INVEGA DIN 02300311
Health Canada record
| Active ingredient(s) | PALIPERIDONE 12 MG |
|---|---|
| Dosage form | Tablet (Extended-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N05AX13 PALIPERIDONE |
| Original market date | |
| Current status date | 30-Jul-2018 |
| Source | Health Canada DPD |
Establishment licence of the holder
Janssen Inc — licence 100239, currently licensed, last inspection rating C (2026-03-09).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PALIPERIDONE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02300273 | INVEGA | JANSSEN INC | Tablet (Extended-Release) | PALIPERIDONE 3 MG | Marketed |
| 02300281 | INVEGA | JANSSEN INC | Tablet (Extended-Release) | PALIPERIDONE 6 MG | Marketed |
| 02300303 | INVEGA | JANSSEN INC | Tablet (Extended-Release) | PALIPERIDONE 9 MG | Marketed |
| 02511037 | MAR-PALIPERIDONE | MARCAN PHARMACEUTICALS INC | Tablet (Extended-Release) | PALIPERIDONE 9 MG | Cancelled Pre Market |
| 02511010 | MAR-PALIPERIDONE | MARCAN PHARMACEUTICALS INC | Tablet (Extended-Release) | PALIPERIDONE 3 MG | Cancelled Post Market |
| 02511029 | MAR-PALIPERIDONE | MARCAN PHARMACEUTICALS INC | Tablet (Extended-Release) | PALIPERIDONE 6 MG | Cancelled Post Market |
| 02456400 | MYLAN-PALIPERIDONE | MYLAN PHARMACEUTICALS ULC | Tablet (Extended-Release) | PALIPERIDONE 3 MG | Cancelled Pre Market |
| 02437139 | MYLAN-PALIPERIDONE | MYLAN PHARMACEUTICALS ULC | Tablet (Extended-Release) | PALIPERIDONE 6 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 9056 | 2007-09-26 | New Drug Submission (NDS) |
International API supply for PALIPERIDONE
40 active FDA Drug Master Files.
Request a quote for INVEGA